VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.16% | 39.27% | 19.41% | 6.28% | -11.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.16% | 39.27% | 19.41% | 6.28% | -11.11% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.16% | 39.27% | 19.41% | 6.28% | -11.11% |
| SG&A Expenses | -1.37% | 5.35% | -1.08% | -8.58% | -18.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.70% | 24.14% | -7.63% | -2.16% | -14.64% |
| Operating Income | -49.14% | -23.97% | 7.96% | 2.27% | 14.68% |
| Income Before Tax | -42.80% | -15.19% | 14.68% | 7.61% | 17.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.82% | -15.14% | 14.72% | 7.65% | 17.89% |
| Earnings from Discontinued Operations | 95.34% | 97.98% | 76.51% | 78.14% | -105.39% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.00% | -5.56% | 18.97% | 13.20% | -22.59% |
| EBIT | -49.14% | -23.97% | 7.96% | 2.27% | 14.68% |
| EBITDA | 56.25% | 77.54% | 60.85% | 25.37% | 14.28% |
| EPS Basic | 86.65% | 91.56% | 76.73% | 48.95% | 5.13% |
| Normalized Basic EPS | 86.33% | 90.80% | 76.48% | 46.09% | 37.03% |
| EPS Diluted | 86.63% | 91.54% | 76.73% | 49.00% | 4.98% |
| Normalized Diluted EPS | 86.33% | 90.80% | 76.48% | 46.09% | 37.03% |
| Average Basic Shares Outstanding | 314.58% | 1,142.83% | 840.37% | 534.40% | 228.77% |
| Average Diluted Shares Outstanding | 314.58% | 1,142.83% | 840.37% | 534.40% | 228.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |